Edition:
India

RTI Surgical Inc (RTIX.OQ)

RTIX.OQ on NASDAQ Stock Exchange Global Select Market

4.80USD
19 Jul 2018
Change (% chg)

-- (--)
Prev Close
$4.80
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
31,557
52-wk High
$5.90
52-wk Low
$3.90

Latest Key Developments (Source: Significant Developments)

RTI Surgical Outlines 2018 Guidance And Long-Term Goals
Friday, 5 Jan 2018 

Jan 5 (Reuters) - RTI Surgical Inc ::RTI SURGICAL OUTLINES 2018 GUIDANCE AND LONG-TERM GOALS.RTI SURGICAL INC - EXPECTS FULL YEAR REVENUES IN RANGE OF $280 MILLION AND $290 MILLION.RTI SURGICAL INC - ‍EXPECTS FULL YEAR EBITDA TO BE IN RANGE OF $32 MILLION TO $38 MILLION​.RTI SURGICAL - CO TO EXPAND REVENUE TO MORE THAN $500 MILLION​ AS ‍LONG-TERM FINANCIAL GOAL, EXPECTED TO BE ACHIEVED WITHIN FIVE YEARS.RTI SURGICAL - CO TO ‍DOUBLE EBITDA MARGIN TO MORE THAN 20 PERCENT AS LONG TERM FINANCIAL GOAL, EXPECTED TO BE ACHIEVED WITHIN FIVE YEARS ​.  Full Article

RTI Surgical Announces Acquisition Of Zyga Technology
Friday, 5 Jan 2018 

Jan 4 (Reuters) - RTI Surgical Inc ::RTI SURGICAL ANNOUNCES ACQUISITION OF ZYGA TECHNOLOGY, INC..RTI SURGICAL INC - TERMS OF DEAL WERE NOT DISCLOSED..RTI SURGICAL - CO TO FUND DEAL WITH CASH AND BORROWING UNDER EXISTING CREDIT FACILITY.  Full Article

RTI Surgical receives warning letter from FDA
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - RTI Surgical Inc :On Nov 9, co received a warning letter from FDA resulting from an inspection of co's facility in Alachua, Florida in April.Warning letter relates to processes used in manufacture of map3 cellular allogeneic bone graft product ​.Warning letter also relates to FDA's views with respect to map3 allograft's regulatory classification​.Warning letter does not restrict production, marketing, or distribution of map3 allograft​.Intends to conduct clinical studies that further confirm safety and efficacy of map3(reg) allograft​.  Full Article

RTI Surgical Q3 earnings per share $0.23
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - RTI Surgical Inc ::RTI Surgical announces 2017 third quarter results.Q3 earnings per share $0.23.Q3 earnings per share view $0.01 -- Thomson Reuters I/B/E/S.Sees FY 2017 adjusted earnings per share $0.05 to $0.07.Sees FY 2017 earnings per share $0.21 to $0.23.Q3 adjusted earnings per share $0.01 excluding items.Sees FY 2017 revenue $274 million to $280 million.Q3 revenue $66.7 million versus I/B/E/S view $65.4 million.FY 2017 earnings per share view $0.06, revenue view $277.8 million -- Thomson Reuters I/B/E/S.  Full Article

RTI Surgical names Robert Jordheim as interim CEO
Wednesday, 14 Dec 2016 

RTI Surgical Inc - : RTI board of directors continues to actively review candidates for permanent chief executive officer position . Jordheim's CFO responsibilities will be assumed on an interim basis by Wy Louw, vice president and controller of RTI . Transition of Jordheim will be completed December 17, 2016 . Jordheim succeeds Brian K. Hutchison .RTI Surgical names Robert P. Jordheim interim CEO.  Full Article

RTI Surgical announces CEO Brian Hutchison to retire
Monday, 15 Aug 2016 

Rti Surgical Inc : RTI surgical announces CEO Brian Hutchison to retire .RTI's board is commencing a search for chief executive officer position.  Full Article

UPDATE 1-Barry Callebaut to boost Ivory Coast cocoa grinding capacity

ABIDJAN, May 22 Switzerland's Barry Callebaut plans to boost the annual grinding capacity of its facilities in Ivory Coast to 230,000 tonnes from 170,000 tonnes by 2022, CEO Antoine de Saint-Affrique said on state-owned broadcaster RTI.